Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents
AssigneeStarton Therapeutics, Inc.
InventorsMarina Borovinskaya, Fotios Plakogiannis, Nisarg Modi, Tamanna Lather, Rod L. Hartwig, James C. Oliver
Life of this patent
Estimating the term…
Abstract
Provided are systems and methods for continuously administering to a subject in need of treatment a formulation comprising an immunomodulatory imide compound. In some embodiments, the method are for use in treating multiple myeloma, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.
Claims20
A transdermal delivery system for delivery of an immunomodulatory imide compound, wherein the transdermal delivery system comprises the immunomodulatory imide compound and a carrier, wherein the immunomodulatory imide compound comprises thalidomide lenalidomide, pomalidomide, iberdomide, or a combination thereof.
The transdermal delivery system of 2, wherein the transdermal delivery system is a transdermal patch.
Dependencies are inferred from the claim text.